The Valley Desk

Clinical trial reportJAMA oncologyPublished

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial

12 of 51 authors shown in byline order.

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
JAMA oncology
Published
Subject terms
Humans; Breast Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Staging; Neoadjuvant Therapy; Adult; Middle Aged; Female; Antibodies, Monoclonal, Humanized; Pathologic Complete Response; Erb-b2 Receptor Tyrosine Kinases
PubMed ID
42530945
Added to directory
Source checked

Report a correction or request removal